Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Telitaciceptum
2. Tai'ai
3. Telitacicept [inn]
4. Telitacicept [who-dd]
5. 1fhm3d7z49
6. 2136630-26-5
7. (l120>a,l121>e,g123>a,a216>s,p217>s)-taci (transmembrane Activator And Caml Interactor, Tumor Necrosis Factor Receptor Superfamily Protein Tnfrsf13b) Human Extracellular Domain Fragment (13-118)-peptide (1-106) Fusion Protein With Human Immunoglobulin G1
8. 13-118-tumor Necrosis Factor Receptor Superfamily Protein Tnfrsf13b (human Extracellular Domain Fragment) Fusion Protein With Immunoglobulin G1, (human Rc18 Fc Fragment), Dimer
9. (l120>a,l121>e,g123>a,a216>s,p217>s)-taci (transmembrane Activator And Caml Interactor, Tumor Necrosis Factor Receptor Superfamily Protein Tnfrsf13b) Human Extracellular Domain Fragment (13-118)-peptide (1-106) Fusion Protein With Human Immunoglobulin G1-(227 C-terminal Residues)-peptide (.gamma.1-chain Fc Fragment) (107-333) (homo Sapiens Ighg1*01, Hinge (107-116), Ch2 L120>a, L121>e, G123>a, A216>s, P217>s (117-226), Ch3 (227-331), Chs (332-333)), (112-112':115-115')-bisdisulfide Dimer,
10. (l120>a,l121>e,g123>a,a216>s,p217>s)-taci (transmembrane Activator And Caml Interactor, Tumor Necrosis Factor Receptor Superfamily Protein Tnfrsf13b) Human Extracellular Domain Fragment (13-118)-peptide (1-106) Fusion Protein With Human Immunoglobulin G1-(227 C-terminal Residues)-peptide (gamma1-chain Fc Fragment) (107-333) (homo Sapiens Ighg1*01, Hinge (107-116), Ch2 L120>a, L121>e, G123>a, A216>s, P217>s (117-226), Ch3 (227-331), Chs (332-333)), (112-112':115-115')-bisdisulfide Dimer,
11. 5,10,15,20-tetrakis(3-iodophenyl)porphyrin
12. 107643-76-5
13. Tetra-(3-iodophenyl)porphin
Molecular Weight | 1118.3 g/mol |
---|---|
Molecular Formula | C44H26I4N4 |
XLogP3 | 13 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 4 |
Exact Mass | Da |
Monoisotopic Mass | Da |
Topological Polar Surface Area | 57.4 |
Heavy Atom Count | 52 |
Formal Charge | 0 |
Complexity | 1010 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of Systemic Lupus Erythematosus (SLE)
ABOUT THIS PAGE
52
PharmaCompass offers a list of Telitacicept API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Telitacicept manufacturer or Telitacicept supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Telitacicept manufacturer or Telitacicept supplier.
PharmaCompass also assists you with knowing the Telitacicept API Price utilized in the formulation of products. Telitacicept API Price is not always fixed or binding as the Telitacicept Price is obtained through a variety of data sources. The Telitacicept Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Telitacicept manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Telitacicept, including repackagers and relabelers. The FDA regulates Telitacicept manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Telitacicept API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Telitacicept supplier is an individual or a company that provides Telitacicept active pharmaceutical ingredient (API) or Telitacicept finished formulations upon request. The Telitacicept suppliers may include Telitacicept API manufacturers, exporters, distributors and traders.
Telitacicept Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Telitacicept GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Telitacicept GMP manufacturer or Telitacicept GMP API supplier for your needs.
A Telitacicept CoA (Certificate of Analysis) is a formal document that attests to Telitacicept's compliance with Telitacicept specifications and serves as a tool for batch-level quality control.
Telitacicept CoA mostly includes findings from lab analyses of a specific batch. For each Telitacicept CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Telitacicept may be tested according to a variety of international standards, such as European Pharmacopoeia (Telitacicept EP), Telitacicept JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Telitacicept USP).